Glucagon-Like Peptide-1 Receptor Agonists: all 1,407 studies that test it

Page 13 of 15. Open to participants first (306), then studies with results posted, then the rest; newest registration first within each.

• Vitamin C and Liraglutide Effects on Hypoglycemia-induced Oxidative Stress, Inflammation and Endothelial Dysfunction in Type 1 Diabetes.WithdrawnNCT02109315Phase 1
• Liraglutide as add-on to Insulin in Type 1 DiabetesCompletedNCT02092896Phase 3
• Safety Evaluation of Adverse Reactions in DiabetesCompletedNCT02092597Phase 4
• Effect of Repeated Administration of Liraglutide on Insulinogenic IndicesCompletedNCT02089256Phase 4
• Exenatide and Weight Loss for Diabetes PreventionCompletedNCT02084654Phase 1
• GLP-1 Response and Effect in Individuals With Obesity Causing Genetic MutationsCompletedNCT02082496Phase 2
• Trial Investigating the Effect of Semaglutide on Energy Intake, Appetite Sensations, Postprandial Glucose and Triglyceride Metabolism and Gastric Emptying in Obese Subjects Compared With PlaceboCompletedNCT02079870Phase 1
• A Trial Investigating the Influence of Oral Semaglutide on the Pharmacokinetics of Lisinopril and Warfarin in Healthy SubjectsCompletedNCT02070510Phase 1
• A Thorough QTc Evaluation of the Effect of Semaglutide on Cardiac Repolarisation in Healthy SubjectsCompletedNCT02064348Phase 1
• Trial Investigating the Absorption, Metabolism and Excretion After a Single Subcutaneous Dose of [3H]-Semaglutide in Healthy Male SubjectsCompletedNCT02060266Phase 1
• A Phase 1b Study of LAPS-Exendin in Subjects of Type 2 Diabetes MellitusStatus unknownNCT02059564Phase 1
• Randomisation to Endobarrier Alone Versus With Incretin Analogue in SustainEd Diabesity (REVISE-Diabesity)Status unknownNCT02055014Phase 4
• Effects of Liraglutide in Young Adults With Type 2 DIAbetes (LYDIA)CompletedNCT02043054Phase 3
• Roux-en-Y Gastric Bypass for BMI 27-32 Type 2 Diabetes Versus Best Medical TreatmentCompletedNCT02041234Phase 4
• Perioperative Insulin, GIK or GLP-1 Treatment in Diabetes MellitusCompletedNCT02036372Not applicable
• Influence of Semaglutide on Pharmacokinetics and Pharmacodynamics of Warfarin and Pharmacokinetics of Metformin in Healthy SubjectsCompletedNCT02022254Phase 1
• Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Hepatic ImpairmentCompletedNCT02016911Phase 1
• Liraglutide Efficacy on Glucocorticoid Induced Hyperglycemia in Patients High Risk for DiabetesStatus unknownNCT02016846Phase 3
• Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Various Degrees of Impaired Renal FunctionCompletedNCT02014259Phase 1
• Efficacy Study of Glucagonlike Peptide-1 to Treat Reperfusion InjuryStatus unknownNCT02001363Not applicable
• Trial of Exenatide for Parkinson's DiseaseCompletedNCT01971242Phase 2
• Exenatide for Stress HyperglycemiaCompletedNCT01969149Phase 2/3
• Exenatide for Myocardial Protection During Reperfusion StudyStatus unknownNCT01938235Phase 2
• Effect of Glucagon-like Peptide 1 (GLP-1) on Microvascular Myocardial Function in Patients With Type 2 Diabetes.CompletedNCT01931982Phase 4
• A Trial to Demonstrate Bioequivalence Between Two Insulin Degludec/Liraglutide Formulations, B5 and V2 in Healthy SubjectsCompletedNCT01916174Phase 1
• Polycystic Ovary Syndrome and Liraglutide as Add-on Therapy on MetforminCompletedNCT01911468Phase 4
• Polycystic Ovary Syndrome and LiraglutideCompletedNCT01899430Phase 4
• Liraglutide in Newly Onset Type 1 Diabetes.CompletedNCT01879917Phase 2/3
• An Open-Label Study Examining the Long-Term Safety of Exenatide Given Twice Daily to Patients With Type 2 Diabetes MellitusCompletedNCT01876849Phase 3
• Investigation on Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of a Long-acting GLP-1 Analogue (Semaglutide) in an Oral Formulation in Healthy Male SubjectsCompletedNCT01866748Phase 1
• Feasibility Study of Exenatide by Continuous Subcutaneous InfusionCompletedNCT01857895Phase 1
• Study of the Acute Metabolic Effect of Exenatide in Type 1 DiabetesCompletedNCT01855490Phase 1
• Does a GLP-1 Receptor Agonist Change Glucose Tolerance in Antipsychotic-treated Patients?Status unknownNCT01845259Phase 2
• A Study to Evaluate the Effect of Ranolazine on Postprandial Glucagon in Subjects With Type 2 Diabetes.CompletedNCT01843127Phase 1
• Evaluating Liraglutide in Alzheimer's DiseaseStatus unknownNCT01843075Phase 2
• Exenatide on GI Motor Function and Permeability in Short Bowel SyndromeWithdrawnNCT01818648Phase 4
• The Impact of Liraglutide on Glucose Tolerance and the Risk of Type 2 Diabetes in Women With Previous Pregnancy-induced DiabetesCompletedNCT01795248Phase 4
• Treatment of Antipsychotic-associated Obesity With a GLP-1 AnalogueCompletedNCT01794429Phase 3
• Effect of Liraglutide Combined With Short-term CSII on Long-term Glycemic Remission and β Cell FunctionStatus unknownNCT01790308Phase 4
• Extension Study for 2993-112CompletedNCT01789957Phase 3
• A Randomised, Double-blind, Placebo-controlled Trial to Assess Safety, Tolerability and Pharmacokinetics of Liraglutide in Obese Adolescent Subjects Aged 12 to 17 YearsCompletedNCT01789086Phase 1
• A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes in Patients With High Baseline HbA1cTerminatedNCT01785771Phase 3
• Differences in Endothelial Function Amongst Sitagliptin and Liraglutide UsersCompletedNCT01785043Phase 4
• Effects of Exenatide on Obesity and/or Diabetes Mellitus Due to Hypothalamic DamageStatus unknownNCT01783717Not applicable
• Incretin Effect on the Immunological PhenotypeCompletedNCT01782261Phase 2
• Effect of Short-Term Intensive Insulin Sequential Exenatide Therapy in Newly Diagnosed Type 2 Diabetic PatientsCompletedNCT01776788Phase 4
• A Randomised, Single Centre, Double-blind, Two-period, Cross-over Trial in Healthy Subjects Investigating the Bioequivalence Between Subcutaneous Injections of Semaglutide Produced by Two Manufacturing ProcessesCompletedNCT01766245Phase 1
• Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 PatientsCompletedNCT01761318Phase 4
• Blood Pressure Outcomes With Liraglutide TherapyCompletedNCT01755572Phase 4
• SAFEGUARD: Pleiotropic Effects of Incretin Based TherapiesCompletedNCT01744236Phase 4
• GLP-1 and Microvascular Function in Type 2 DiabetesCompletedNCT01740921Not applicable
• Influence of Appetite Related Hormones in Binge Eating Behaviour Among the Overweight and ObeseCompletedNCT01739049Phase 4
• Anti-diabetic Effects of Liraglutide in Adolescents and Young Subjects With Type 1 DiabetesWithdrawnNCT01722227Phase 3
• The Influence of Liraglutide on the Reward Properties of Food: an fMRI Study on Healthy VolunteersCompletedNCT01695109Phase 4
• Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long-acting GLP-1 Analogue in Healthy Male Subjects and Male Subjects With Type 2 DiabetesCompletedNCT01686945Phase 1
• Effects of Liraglutide on Kidney Function in Type 2 Diabetic PatientsCompletedNCT01664676Phase 4
• Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DMCompletedNCT01658501Phase 2
• Study of Effectiveness of Liraglutide Added to High Dose Insulin in Type II DiabeticsCompletedNCT01654120Phase 4
• Study of Liraglutide in Individuals With Type 2 Diabetes Using InsulinTerminatedNCT01628445Phase 3
• Safety and Tolerability of Liraglutide in Healthy Japanese VolunteersCompletedNCT01620476Phase 1
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Healthy Japanese VolunteersCompletedNCT01620463Phase 1
• Pharmacoscintigraphic Investigation of NN9924 in Healthy Male SubjectsCompletedNCT01619345Phase 1
• Safety and Tolerability of Liraglutide in Japanese Subjects With Type 2 DiabetesCompletedNCT01615978Phase 1
• Liraglutide in Type 1 DiabetesCompletedNCT01612468Phase 4
• The Effects of GLP-1 in Maturity-Onset Diabetes of The Young (MODY)CompletedNCT01610934Phase 2/3
• Impact of Liraglutide on Sensory Perception, Sensory Specific Satiety, Liking and Wanting in Type 2 Diabetic PatientsCompletedNCT01599338Not applicable
• Combinatorial Therapy for Peristent Type 2 Diabetes After Gastric BandingTerminatedNCT01597531Phase 4
• The Effect of Liraglutide on the Treatment of Coronary Artery Disease and Type 2 DiabetesCompletedNCT01595789Phase 4
• A Long-term Trial to Compare the Effects of Liraglutide and Sulphonylurea (Glimepiride) Both in Combination With Metformin on Clinical, Endothelial and Image Markers of Cardiovascular Risk in Patients With Type 2 DiabetesWithdrawnNCT01593137Phase 4
• GLP-1 Analogue Treatment in Uncontrolled Type 1 Diabetic PatientsStatus unknownNCT01592279Phase 4
• DIabetes REsearCh on Patient sTratification (DIRECT): GLP-1R AgonistsCompletedNCT01575301Not applicable
• Pharmacology of Exenatide in Pediatric SepsisWithdrawnNCT01573806Phase 1/2
• Investigation of Optimal Dosing Conditions for a Long Acting GLP-1 Analogue in Healthy Male SubjectsCompletedNCT01572753Phase 1
• Liraglutide Effects on Memory in Healthy SubjectsCompletedNCT01550653Phase 1
• Liraglutide Use in Prader-Willi SyndromeTerminatedNCT01542242Phase 4
• The Effect of Liraglutide Adjunct to Insulin on Glucagon Response to Hypoglycaemia in Subjects With Type 1 DiabetesCompletedNCT01536665Phase 1
• Effect of Liraglutide on Gastrointestinal Absorption of Several Drugs and Potential Influence of Liraglutide on Intragastric pHCompletedNCT01518166Phase 1
• Vildagliptin Versus Liraglutide - Patient Preference After Receiving Both MedicationsCompletedNCT01518101Phase 4
• Metabolism and Excretion of Liraglutide in Healthy Male VolunteersCompletedNCT01517568Phase 1
• Effect of Liraglutide on Absorption of Paracetamol in Subjects With Type 2 DiabetesCompletedNCT01517555Phase 1
• Study of RO6807952 in Patients With Diabetes Mellitus Type 2TerminatedNCT01516476Phase 2
• Effect of Liraglutide on Heart Frequency in Healthy VolunteersCompletedNCT01516255Phase 1
• Safety and Tolerability of Liraglutide in Healthy Japanese Male VolunteersCompletedNCT01515592Phase 1
• Comparison of Two Liraglutide Formulations in Healthy SubjectsCompletedNCT01515579Phase 1
• Bioequivalence of Two Liraglutide Formulations in Healthy VolunteersCompletedNCT01515553Phase 1
• Comparison of Three Liraglutide Formulations in Healthy VolunteersCompletedNCT01514487Phase 1
• Comparison of Liraglutide Injected at Three Different Injection Sites in Healthy VolunteersCompletedNCT01513525Phase 1
• Effect of Liraglutide Compared to Glimepiride on Appetite in Subjects With Type 2 DiabetesCompletedNCT01511692Phase 1
• Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic AgentCompletedNCT01511198Phase 2
• Effect of Liraglutide on the Beta-cell Responsiveness in Subjects With Type 2 Diabetes Compared to a Healthy Control GroupCompletedNCT01511185Phase 1
• Effect of Liraglutide as add-on to Metformin Compared to Either Liraglutide or Metformin Alone, or to a Combination of Metformin and a SU (Sulphonylurea) Agent in Subjects With Type 2 DiabetesCompletedNCT01511172Phase 2
• Comparison of Liraglutide Inhaled Into the Lungs Compared to Liraglutide Injected Under the Skin in Healthy Male VolunteersCompletedNCT01511159Phase 1
• Comparison of Liraglutide and Glimepiride on Blood Sugar Control in Subjects With Type 2 DiabetesCompletedNCT01509755Phase 2
• Effect of Liraglutide on Glucagon Secretion in Subjects With Type 2 DiabetesCompletedNCT01509742Phase 1
• Effect of Liraglutide on Weight and Appetite in Obese Subjects With Type 2 DiabetesCompletedNCT01508949Phase 2
• Effect of Liraglutide on Glucose Profiles and Gastric Emptying in Subjects With Type 2 DiabetesCompletedNCT01508923Phase 2
• Comparison of Two Liraglutide Formulations in Healthy VolunteersCompletedNCT01508897Phase 1
• Influence on the Effect of an Oral Contraceptive Drug After Administration of Liraglutide in Postmenopausal WomenCompletedNCT01508858Phase 1
• Safety and Tolerability of Liraglutide in Subjects With Impaired Kidney Function and in Subjects With Normal Kidney FunctionCompletedNCT01508806Phase 1
• Safety of Liraglutide in Subjects With Liver Impairment and in Subjects With Normal Liver FunctionCompletedNCT01507389Phase 1

← Glucagon-Like Peptide-1 Receptor Agonists overview